GOVX
GeoVax Labs, Inc.
There isn't enough reported data to score GOVX yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
GOVX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
GOVX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
GOVX PE Valuation
GOVX has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
GOVX Forward outlook
There aren't enough analyst estimates for GOVX to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
GOVX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$5,728.74 | +$1,741.26 |
| Q2 2024 | -$8,062.74 | -$1,942.74 |
| Q1 2024 | -$8,848.74 | -$3,088.74 |
| Q4 2023 | -$8,716.74 | -$1,246.74 |
| Q3 2023 | -$7,470.00 | +$18,810.00 |
| Q2 2023 | -$6,120.00 | +$21,420.00 |
| Q1 2023 | -$5,760.00 | +$22,050.00 |
| Q4 2022 | -$7,470.00 | +$19,890.00 |
OSCR has the stronger earnings trend. Trailing diluted EPS is down 104% for GOVX versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
GOVX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $852.3K | +183% |
| Q1 2022 | $81.5K | -26% |
| Q4 2021 | $165K | -34% |
| Q3 2021 | $30.4K | -93% |
| Q2 2021 | $79.7K | -82% |
| Q1 2021 | $110.4K | -85% |
| Q4 2020 | $251.6K | -6.3% |
GOVX's revenue has slid since its 2024 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -636% | +1048 points |
| Q1 2025 | -330% | N/A |
| Q4 2024 | -965% | N/A |
| Q3 2024 | -210% | N/A |
| Q2 2024 | -1684% | N/A |
| Q1 2022 | -2978% | -1562 points |
| Q4 2021 | -8331% | -7800 points |
| Q3 2021 | -6416% | -6311 points |
GOVX's operating margin was −636% last quarter, up 1048 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over GOVX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
GOVX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.3M | +$1.9M |
| Q2 2026 | -$3.7M | +$687K |
| Q1 2026 | -$3.5M | +$2.4M |
| Q4 2025 | -$5M | +$2.8M |
| Q3 2025 | -$6.2M | +$3.1M |
| Q1 2025 | -$6M | -$298.8K |
| Q4 2024 | -$7.8M | +$2.5M |
| Q3 2024 | -$9.3M | -$4.2M |
GOVX has burned cash in almost every quarter: −$16M over the past year, against −$24M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over GOVX on cash generation, producing positive trailing cash flow while its opponent burns cash.
GOVX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +107% | +203K shares |
| 1 year | +1064% | +360K shares |
| 3 years | +13295% | +391K shares |
| 5 years | +452256% | +393K shares |
GOVX has 393,550 diluted shares, up 1064% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over GOVX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
GOVX Net Leverage
GOVX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
GOVX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.7 | Oversold |
| Stochastic | 1.4 | Oversold |
GOVX's weekly RSI is 29 (oversold) and its Stochastic is 1 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
GOVX PE vs Healthcare Sector
GOVX has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
GOVX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.42 | 62% below |
| 20 week MA | $12.9 | 84% below |
| 50 week MA | $43.4 | 95% below |
| 100 week MA | $349.0 | 99% below |
| 200 week MA | $1,907.6 | 100% below |
GOVX is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over GOVX on trend strength, trading above more of its moving averages.
GOVX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $143,928.0 | $29,520.0 | -79% |
| 2021 | $29,520.0 | $36,180.0 | +23% |
| 2022 | $36,180.0 | $5,106.5 | -86% |
| 2023 | $5,106.5 | $3,249.1 | -36% |
| 2024 | $3,249.1 | $1,476.0 | -55% |
| 2025 | $1,476.0 | $108.7 | -93% |
| 2026 YTD | $108.7 | $2.04 | -98% |
GOVX has finished four years in a row lower, and it's down 98% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over GOVX on returns for 2026, with the stronger performance.